Sign in Subscribe
Cancer research

Cizzle Bio Submits NIH Grant Application for Two-Year Study on CIZ1B Biomarker for Early-Stage Lung Cancer Detection

Strategic Insights

— 1 min read

Cizzle Bio, a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric cancers, has submitted a grant application to the National Institutes of Health (NIH) to support a two-year study validating its CIZ1B biomarker for early-stage lung cancer detection. The study aims to analyze pre-diagnostic and longitudinal blood plasma samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to determine whether the CIZ1B biomarker can detect lung cancer prior to clinical symptoms.

Key Takeaways:

  • The proposed study will use a large cohort of 1,730 lung cancer cases to evaluate CIZ1B performance across age, gender, ethnicity, smoking history, and other demographic and behavioral subgroups.
  • Researchers will investigate whether early biomarker changes are associated with more aggressive forms of the disease and assess detection accuracy across different lung cancer histological subtypes.
  • A key objective is to identify the optimal window for detection and determine how far in advance the biomarker can signal the onset of cancer before clinical diagnosis.
  • The study will be conducted in partnership with the Florida Institute for Human and Machine Cognition (IHMC) and the Southwest Research Institute (SwRI), with IHMC leading the development of deep learning models to correlate biomarker expression with cancer onset.
  • CIZ1B has demonstrated high sensitivity and specificity in earlier studies of Stage 1 lung cancer, conducted by Cizzle Biotechnology at the University of York in the UK.
  • The proposed study is expected to demonstrate the potential role of CIZ1B in filling a critical gap in early lung cancer detection, enabling earlier intervention to improve patient outcomes.
  • Broad adoption of the CIZ1B test could lead to substantial healthcare savings by helping reduce the high costs associated with treating late-stage lung cancer.

Statistics:

  • 1,730 lung cancer cases will be analyzed in the proposed study.
  • CIZ1B has demonstrated high sensitivity and specificity in earlier studies of Stage 1 lung cancer, with [X] sensitivity and [X] specificity.
  • The proposed study aims to identify the optimal window for detection, with a goal of detecting cancer [X] months before clinical diagnosis.
  • The study is expected to assess detection accuracy across different lung cancer histological subtypes, with a total of [X] subtypes to be analyzed.

Sources:

  • "Cizzle Bio Submits NIH Grant Application for Two-Year Study on CIZ1B Biomarker for Early-Stage Lung Cancer Detection" (PRNewswire, 2025)
  • Cizzle Bio, Inc. (About Us)
  • Florida Institute for Human and Machine Cognition (IHMC) (About Us)
  • Southwest Research Institute (SwRI) (About Us)

Read more